ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. O'Shaughnessy on Avastin as Her Standard of Care

Joyce A. OShaughnessy, MD
Published: Wednesday, Aug 17, 2011

Program Director Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, explains that Avastin (bevacizumab) remains her standard of care for aggressive metastatic breast cancer that requires the use of two agents for optimal control.

She explains that the using two chemotherapy agents may not be sustainable for longer periods of time; whereas paclitaxel in combination with Avastin offers better options for doublet therapy. She believe that Avastin also fulfills is biggest unmet medical need in triple negative breast cancer which is often refractory to chemotherapy.
Program Director Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, explains that Avastin (bevacizumab) remains her standard of care for aggressive metastatic breast cancer that requires the use of two agents for optimal control.

She explains that the using two chemotherapy agents may not be sustainable for longer periods of time; whereas paclitaxel in combination with Avastin offers better options for doublet therapy. She believe that Avastin also fulfills is biggest unmet medical need in triple negative breast cancer which is often refractory to chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x